Literature DB >> 10981029

Update on Clostridium difficile infection.

C S Alcantara1, R L Guerrant.   

Abstract

Clostridium difficile is a major cause of antibiotic-associated diarrhea in hospital and community settings, spreading endemic and epidemic disease in developed and developing areas throughout the world. Its toxins A and B cause epithelial disruption, inflammation, and secretion. Diagnosis of infection with C. difficile is based on appropriate clinical presentation and demonstration of the presence of either toxin A or B, or both. Established treatment is still predominantly metronidazole and vancomycin. The association of antibiotic therapy with recurrent disease and antimicrobial resistance, especially vancomycin-resistant enterococci, highlights the need for new approaches to managing C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981029     DOI: 10.1007/s11894-000-0024-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  47 in total

Review 1.  How intestinal bacteria cause disease.

Authors:  R L Guerrant; T S Steiner; A A Lima; D A Bobak
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

2.  Risk factors for early recurrent Clostridium difficile-associated diarrhea.

Authors:  A N Do; S K Fridkin; A Yechouron; S N Banerjee; G E Killgore; A M Bourgault; M Jolivet; W R Jarvis
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

3.  Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes.

Authors:  K K Jefferson; M F Smith; D A Bobak
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

4.  A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.

Authors:  O Karlström; B Fryklund; K Tullus; L G Burman
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

5.  Role of platelet activating factor in the inflammatory and secretory effects of Clostridium difficile toxin A.

Authors:  M Fonteles; G Fang; N M Thielman; P S Yotseff; R L Guerrant
Journal:  J Lipid Mediat Cell Signal       Date:  1995-03

6.  Epidemiology of community-acquired Clostridium difficile-associated diarrhea.

Authors:  L R Hirschhorn; Y Trnka; A Onderdonk; M L Lee; R Platt
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

7.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

Authors:  M B Edmond; J F Ober; D L Weinbaum; M A Pfaller; T Hwang; M D Sanford; R P Wenzel
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

Review 8.  Pathogenesis of Clostridium difficile infection.

Authors:  S P Borriello
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

9.  The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins.

Authors:  I Just; M Wilm; J Selzer; G Rex; C von Eichel-Streiber; M Mann; K Aktories
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

Review 10.  Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease.

Authors:  F Frost; G F Craun; R L Calderon
Journal:  Emerg Infect Dis       Date:  1998 Oct-Dec       Impact factor: 6.883

View more
  3 in total

1.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Clostridium difficile colitis.

Authors:  Judith L Trudel
Journal:  Clin Colon Rectal Surg       Date:  2007-02

3.  Steroid-refractory ulcerative colitis treated with corticosteroids, metronidazole and vancomycin: a case report.

Authors:  Jonathan Miner; M Monem Gillan; Philip Alex; Michael Centola
Journal:  BMC Gastroenterol       Date:  2005-01-24       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.